Two Patients at Jacobi Enrolled in APEX-AV Study, an Important PE Trial using AlphaVac System from AngioDynamics
Per AngioDynamics, “ APEX-AV is a single-arm Investigational Device Exemption study enrolling patients with confirmed acute, intermediate-risk PE at up to 20 hospital-based sites in the United States . The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint is the rate of Major Adverse Events, including device-related death and major bleeding within the first 48 hours. Patients will be followed for 30 days post-index procedure. We are privileged to have the first patient enrolled in this important PE trial using the AlphaVac F1885 System at Jacobi Medical Center. The procedure time was less than 60 minutes, and we were particularly impressed with the design, control, and navigability that the 18F cannula provides,” said Seth Sokol, MD, Cardiology Specialist, Jacobi Medical Center, and the site Principal Investigator. ”
7
Made with FlippingBook interactive PDF creator